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Report 
The Role of MYCN in the Failure of MYCN Amplified Neuroblastoma  
Cell Lines to G1 Arrest After DNA Damage
ABsTRACT
We previously reported that 3 p53 wild type (wt) MYCN amplified (MNA) neuro-
blastoma cell lines failed to G1 arrest after DNA damage despite induction of p53, 
p21WAF1 and MDM2. We hypothesised that this was due to high MYCN expression. p53 
responses to DNA damage were examined in an additional 13 p53 wt neuroblastoma 
cell lines. MNA was significantly associated with a failure to G1 arrest after DNA damage 
(p < 0.001) and higher levels of apoptosis after irradiation (p < 0.05). p21WAF1 and 
hypophosphorylated (hypo) RB accumulation post irradiation were significantly lower in 
cell lines that failed to G1 arrest (p < 0.05). Conditional MYCN expression in non-MNA 
SHEP Tet21N cells did not affect the G1 arrest after irradiation. MYCN knockdown using 
siRNA in 3 p53 wt MNA cell lines did not restore a G1 arrest after irradiation, but 
increased the baseline G1 population, p21WAF1 and hypo RB expression. MYCN siRNA 
also caused a G1 arrest in a p53 mutant MNA cell line. This study is the first to deter-
mine that MNA correlates with a failure to G1 arrest and attenuated p21WAF1 induction; 
however MYCN expression alone is not causally responsible.
InTRoDUCTIon
The MYCN oncogene is amplified in 25% of neuroblastoma and is strongly associated 
with a poor prognosis.1 MYCN is located on chromosome 2p24 and encodes a 60–63 kDa 
transcription factor that is a member of the MYC family. MYC transcription factors have a 
conserved structure which includes a transcriptional activation domain in the N-terminus 
and a C-terminus basic helix-loop-helix/leucine zipper domain that plays a role in protein 
dimerisation, sequence specific DNA binding and the regulation of transcription.2 MYCN 
heterodimerises with MAX and binds to E-box DNA sequences in promoters of MYCN 
target genes. MYCN expression is limited to central and peripheral nervous systems, 
kidney, lungs and spleen during embryonic development, unlike its counterpart MYC that 
is expressed in multiple tissues at all stages of development.3
A number of studies have characterised the role of MYCN in tumor progression and 
tumorigenicity. A transgenic mouse model, in which high levels of MYCN were expressed 
in neuroectodermal cells, developed neuroblastoma with chromosomal losses and gains 
in regions orthologous to those found in human neuroblastoma.4,5 Reduction of MYCN 
expression using MYCN antisense oligonucleotides in the same model decreased prolifera-
tion and induced neuronal differentiation of neuroblastoma cells.6 Conditional expression 
of MYCN in a non-MNA neuroblastoma cell line has been shown to shorten the time taken 
to progress through the cell cycle, increase proliferation and decrease attachment of cells to 
the extra-cellular matrix.7 Although MNA is a poor prognostic indicator, the clinical role of 
MYCN expression has not been as clearly defined. A recent report has suggested that high 
levels of MYCN expression in tumors lacking amplification is associated with a favorable 
prognosis, and induced expression of MYCN in p53 mutant SK-N-AS cells slows growth 
by increasing levels of apoptosis and increasing the expression of favorable genes.8
p53 has been described as ‘the guardian of the genome’.9 After DNA damage, p53 
binds DNA in a sequence specific manner and activates the transcription of a number of 
genes including MDM2, BAX and p21WAF1. MDM2 forms an auto-regulatory feedback 
loop with p53. The induction of p21WAF1, a cyclin-dependent kinase inhibitor, induces 
a G1 arrest until DNA has been repaired or apoptosis has been initiated.
10 p53 has been 
described as the most frequently mutated gene in human cancer and is particularly preva-
lent in adult malignancies; however several studies have found that p53 mutations in both 
neuroblastoma tumors and cell lines are rare.11,12 When p53 mutations do occur they 
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are in progressive and relapsed neuroblastoma, suggesting that p53 
mutations occur as a mechanism for resistance to cytotoxic drugs that 
target the p53 pathway.11 Other aberrations in the p53 pathway have 
been described to occur at relapse, such as MDM2 amplification, and 
p14ARF deletion and methylation.13 MDM2 has been shown to be a 
direct transcriptional target of MYCN, with MYCN binding to the 
E-box in the P2 promoter region of MDM2. Slack et al propose that 
MYCN expression decreases the stability of p53 through increasing 
levels of MDM2 expression, consequently inhibiting MYCN driven 
apoptosis.14
An attenuated G1 arrest in response to DNA damage has been 
observed in some wt p53 neuroblastoma cell lines despite induction 
of p53, MDM2 and p21WAF1.15-18 It has previously been reported 
that the MNA, p53 wt cell lines SK-N-BE(1n), IMR-32 and NGP 
all fail to undergo a G1 arrest in response to DNA damage and the 
non-MNA cell lines SHEP, SKNSH and SH-SY-5Y all undergo a G1 
arrest post irradiation.17,18 This suggests that a failure to G1 arrest 
is linked to MNA. In this study, the p53 responses to DNA damage 
were investigated in a further seven MNA and six non-MNA p53 wt 
cell lines to extend the above observations. To test the hypothesis that 
high MYCN expression is causally linked to a failure to undergo a G1 
arrest in response to DNA damage, MYCN expression was manipu-
lated in the non-MNA SHEP cell line with a tetracycline regulated 
Tet21N MYCN expression vector. In addition MYCN was knocked 
down using siRNA in four MNA cell lines to determine if reduction 
of MYCN would restore a G1 arrest in response to DNA damage.
mATERIALs AnD mEThoDs
Tissue culture. Seventeen p53 wt human Mycoplasma-free neuro-
blastoma cell lines were studied.13 The non-MNA cell lines were: 
SJNB-1,19 NBL-S,20 SKNRA,12 SHSY5Y,21 LAN-6,22 NB6923 and 
GIMEN24 and the MNA neuroblastoma cell lines were IMR-32, 
NGP,25 PER-108,26 CHLA-136, SMSKCNR12 TR14,27 LS,28 
CHP902R,29 SKNBE(1n)18 and NBLW.30 The MNA p53 mutant 
cell line SKNBE(2c) with a missense mutation in exon 5 codon 
135: TGC (cysteine) to TTC (phenylalanine)18 was used for siRNA 
experiments. All cell lines were grown in RPMI 1640 (Gibco, Paisley, 
UK) supplemented with 10% FCS (Gibco). Cells were grown at 
37˚C, in a humidified incubator with 5% CO2.
DNA damage by g‑irradiation. Cells were plated in 28 cm2 tissue 
culture dishes (Nunc, Naperville, IL) at 5 x 105 cells per plate and 
irradiated when ~70% confluent with 4 Gy 310 kV X-rays from a 
RS320 irradiation system (Gulmay Medical, Surrey, UK). Cells were 
harvested 2, 6 and 24 hors post irradiation for Western blotting and 
24 hours post irradiation for cell cycle analysis. Experiments were 
carried out at least n = 2.
Protein lysate preparation and Western blotting. Whole cell 
extracts were prepared, and 30 mg protein/sample separated by gel 
electrophoresis and Western blotting performed using methods 
previously described.17 Densitometry was performed using a Fuji-Las 
camera and the AIDA image analyser program (Raytek, Sheffield, 
UK) used to quantify band intensities.
Antibodies. Primary antibodies used were mouse monoclonal p53 
DO7 at 1:1000 dilution (Novocastra, Newcastle, UK), MDM2 at 
1:100, p21WAF1 at 1:100 (Calbiochem, Cambridge, MA), hypophos-
phorylated retinoblastoma protein (Hypo RB) at 1:100 and total 
retinoblastoma protein at 1:500, both from BD biosciences (Oxford 
UK) and the mouse monoclonal MYCN 100 antibody at 1:10 (gift 
from N. Igekaki). b-actin rabbit polyclonal used as a protein loading 
and transfer control at 1:1000 (Sigma, St Louis, MO). The secondary 
goat anti-mouse IgG and goat-anti rabbit IgG antibodies were both 
HRP conjugated and used at 1:1000 (DAKO, Glostrup, Denmark).
SHEP Tet21N MYCN expression system. The SHEP Tet21N 
cell line7 was grown in RPMI 1640 supplemented with 10% 
tetracycline-free FCS (Clontech, Mountain View, CA) G418 and 
Hygromycin (Promega, Southampton, UK). SHEP Tet21N cells 
express MYCN in the absence of tetracycline. To switch off MYCN 
expression, 10 ng/ml Tetracycline (Sigma) was added to the growth 
media at least 24 hours prior to experiments.
Flow cytometry. Adherent cells (~2 x 106) were harvested with 
trypsin 24 hours post irradiation, fixed in ice cold 70% Ethanol 
30% PBS solution and stored at 4˚C. Cells were resuspended in 
fresh PBS with 40 mg/ml propidium iodide and 0.1 mg/ml RNAse 
A (Sigma) and incubated at 37˚C for 30 minutes. Measurements 
were performed using a FACScan (Becton Dickinson Oxford, UK) 
and analysed using Cell Quest software (Beckton Dickinson) and 
WinMDI software (TSRI, La Jolla, USA). Cell cycle experiments 
were performed in triplicate.
Apoptosis measurements. Apoptosis measurements using Hoechst 
and FACs were carried out as described previously.17 Cells were 
harvested 24, 48, 72 and 96 hours post irradiation, and apoptosis 
experiments for both methods were carried out in triplicate.
MYCN expression measured by quantitative reverse transcrip‑
tase PCR. RNA extraction, reverse transcriptase PCR and real time 
PCR was carried out as described in Carr et al.13 Primers and probes 
for both the MYCN and the b-Actin control were Taqman assays 
from Applied Biosystems (Foster City, CA). Each of the samples 
were run in triplicate on a 384 well plate using a ABI prism 7900 
detection kit (Applied Biosystems). Each experiment was carried out 
in triplicate.
Table 1	 Densitometry	results	for	Western	blots	of	ten			
	 MNA and	seven	non-MNA	neuroblastoma		
	 cell	lines	after	irradiation	showing	maximal	
	 p53,	p21WAF1,	MDM2	and	hypo	RB	induction		
	 with	times	of	maximal	induction
 Cell Line myCn status  p53 mDm2 p21wAF1 hypo Rb
 GIMEN Non-MNA 1.2 2 h 12.8 6 h 3.0 24 h 1.2 24 h
 NB-69 Non-MNA 1.5 6 h 1.9 6 h 0.3 6 h 0.8 6 h
 SJNB-1 Non-MNA 0.8 6 h 0.8 6 h 1.8 6 h 1.2 6 h
 NBL-S Non-MNA 0.6 6 h 1.2 6 h 0.8 6 h 1.8 6 h
 LAN-6 Non-MNA 0.7 6 h 0.8 6 h 2.1 24 h 1.0 6 h
 SKNRA Non-MNA 1.1 6 h 1.0 6 h 2.7 24 h 2.1 24 h
 SH-SY-5Y Non-MNA 1.0 2 h 4.4 6 h 1.5 24 h 3.7 24 h
 PER-108 MNA 1.7 6 h 1.2 6 h 1.2 24 h 1.6 6 h
 SKNBE(1n) MNA 2.1 6 h 0.4 6 h 0.1 6 h 0.7 6 h
 CHP902R MNA 0.6 6 h 0.6 6 h 0.6 24 h 1.2 24 h
 IMR-32 MNA 1.7 2 h 1.6 24 h 0.2 24 h 0.6 2 h
 NGP MNA 0.4 6 h 3.1 6 h 0.5 24 h 0.6 6 h
 SMSKCNR MNA 0.8 6 h 0.8 6 h 0.3 24 h 0.6 6 h
 CHLA-136 MNA 1.5 6 h 0.5 6 h 0.6 24 h 0.3 6 h
 NBLW MNA 1.1 6 h 1.0 6 h 0.2 6 h 0.4 2 h
 LS MNA 0.3 24 h 3.9 24 h 0.1 6 h 0.6 6 h
 TR14 MNA 0.1 6 h 3.1 24 h 0.2 6 h 0.9 2 h
30 mg protein was loaded for each sample and all densitometry results were normalised to a positive control 
(6 h irradiated SKNRA).
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RNA Interference of MYCN. Small interfering RNA (siRNA) 
oligonucleotides targeted against exon 2 of MYCN were synthe-
sised by Eurogentec (Seraing, Belgium). The sense strand of the 
MYCN siRNA sequence was: UGAUCUGCAAGAACCCAGA. 
A scrambled sequence of the MYCN siRNA was used as a 
negative control. The scrambled (SCR) control sequence was: 
AUGUUAUCUGGCCCGUGUA. A BLAST™ database search 
was carried out against the human genome (nucleotide database) to 
ensure that MYCN and SCR sequences had no cross reactivity with 
other gene transcripts. MYCN siRNA was transiently transfected 
into cells at final concentrations of either 25 nM for NGP and 
SKNBE(2c) or 40 nM for IMR-32 and NBLW using Lipofectamine 
(Invitrogen, Paisley, UK) for 24 hours according to manufacturer’s 
instructions. Knock down of MYCN using siRNA was monitored 
by Western blot analysis and performed in 4 MNA neuroblastoma 
cell lines: p53 wt IMR-32, NBLW, NGP and the p53 mutant cell 
line SK-N-BE(2c). The results for FACs cell cycle and Western blot 
densitometry displayed in the figures were for the concentration of 
siRNA that gave the most consistent cell cycle results and percentage 
MYCN knockdown. Optimal MYCN knockdown was at 16 hours 
and was measured 48 hours later before an increase in MYCN 
returned.
Statistics. For statistical tests, some data sets did not have a normal 
distribution, (determined using an Anderson Darling Normality test) 
so a Mann Whitney test was used throughout with the level of statis-
tical significance taken as p < 0.05.
Figure 1. (A) Western blots for p53, MDM2, p21WAF1, Hypo RB and b-actin in 17 cell lines 2, 6 and 24 hours post irradiation. The positive control is the 
6h irradiated SKNRA sample. (B) Bar graph showing the normalised expression of p21WAF1 at 6 hours post irradiation for all 17 cell lines tested. Levels of 
p21WAF1 protein expression were significantly lower in MNA cell lines compared with non MNA cell lines (p < 0.01). Cell lines were irradiated n = 2.
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REsULTs
p53 transcriptional function in response to DNA damage. The 
p53 functional response to DNA damage was investigated using 
Western blotting for p53, MDM2, p21WAF1 and hypo RB in 17 
p53 wt neuroblastoma cell lines, 7 non-MNA and 10 MNA cell lines 
(Table 1 and Fig. 1). Each sample was compared to a positive control 
(the 6 hours post irradiation SKNRA sample). The non-MNA 
SKNRA cell line has previously been reported to have an intact p53 
response to DNA damage.12
The non-MNA cell lines: GIMEN, SJNB-1, SKNRA, LAN-6, 
NBL-S, SHSY5Y all had higher levels of p21WAF1 induction after 
DNA damage compared with MNA cell lines (Fig. 1A and B). 
The NB69 non-MNA cell line had relatively low levels of p21WAF1 
and hypo RB after irradiation (Fig. 1 and Table 1). Lower levels of 
p21WAF1 and hypo RB induction were observed in 9/10 MNA cell 
lines: SMSKCNR, CHLA-136, IMR-32, NBLW, NGP, TR14, LS, 
SKNBE1n and CHP902R (Fig. 1 and Table 1). The MNA PER-108 
cell line had higher levels of p21WAF1 and hypo RB induction 
compared with other MNA cell lines, similar to levels in non-MNA 
cell lines (Fig. 1). Levels of p21WAF1 induction 6 and 24 hours post 
irradiation were significantly lower in MNA compared with non-
MNA cell lines (p < 0.01 and p < 0.05) (Fig. 1B) and levels of hypo 
RB were significantly lower 6 and 24 hours post irradiation (p < 0.01). 
Comparison of induced p53 and MDM2 levels showed no significant 
difference between MNA and non-MNA cell lines (Table 1).
Cell cycle arrest after irradiation of cell lines. The SKNRA cell 
line shown in Figure 2A as an example of a non-MNA cell line, 
underwent a significant G1 arrest 24 hours after irradiation (p < 
0.001). The proportion of cells in G1 increased from 78.4 ± 1.2% 
to 88.0 ± 1.4% and the proportion in S-phase decreased from 9.8 ± 
0.5% to 1.6 ± 0.1%. The G1:S ratio increased from 8.3 ± 0.5 to 60.8 
± 8.7 post irradiation (Fig. 2A and C). All six non-MNA cell lines 
underwent a G1 arrest in response to DNA damage (Fig. 2A and C). 
Cell cycle data for the non-MNA NBL-S cell line is consistent with 
a previous report showing a significant G1 arrest after irradiation in 
this cell line.31
The MNA NBLW cell line failed to undergo a G1 arrest in 
response to DNA damage (Fig. 2B and C). The G1:S ratio did not 
change significantly between the control (2.8 ± 0.1) and 24 hours 
post irradiation samples (3.3 ± 0.7). The proportion of cells in G1 
decreased from 60.6 ± 0.8% to 43.8 ± 0.8% after irradiation and 
the proportion of S-phase cells decreased from 21.3 ± 0.7% to 17.5 
± 2.7% and cells accumulated in G2 increasing from 18.4 ± 0.8% 
to 39.0 ± 2.1% (Fig. 2B). Six of the seven MNA cell lines NBLW, 
SMSKCNR, CHLA-136, CHP902R, TR14, and LS failed to G1 
arrest after irradiation. The G1:S ratios decreased or remained the 
same after irradiation (Fig. 2B and C). The G1:S ratio of the MNA 
CHP902R cell line increased after irradiation, however this was not 
statistically significant (p = 0.13). The only MNA cell line that did G1 
arrest was the PER-108 cell line, which also has higher levels of p21WAF1 
and hypo RB induction after irradiation (Table 1 and Fig. 1).
Cell cycle data from the 13 cell lines analysed in the current study 
was combined with existing data on NGP, IMR-32, SK-N-BE(1n), 
SHEP, SK-N-SH and SH-SY-5Y cell lines from17 and18 in Figure 2D. 
MNA cell lines had significantly lower increases in G1:S ratio after 
irradiation when compared with non-MNA neuroblastoma cell lines 
(p < 0.001).
Apoptosis after irradiation induced DNA damage. The apoptotic 
response to irradiation was compared in five non-MNA and eight 
MNA neuroblastoma cell lines including four previously studied 
cell lines17,18 (Fig. 3). The non-MNA LAN-6, SJNB-1, GIMEN, 
SHSY5Y and SKNRA cell lines underwent lower levels of apoptosis 
measured by Hoechst staining following irradiation compared with 
PER-108, NBLW, CHLA-136, LS and SMSKCNR MNA cell lines. 
Maximal levels of apoptosis at 96 hours were 5-24% by Hoechst and 
16–36% by FACs for the above non-MNA cell lines compared with 
42–70% apoptosis for the above MNA cell lines (Fig. 3A–C). The 
Figure 2. Cell cycle data. a) Cell cycle histograms for non-MNA SKNRA and 
b) MNA NBLW cell lines. Cont = non-irradiated cells and Irrad = 24 hour 
post irradiated samples. c) Summary of cell cycle data, displayed as G1:
S ratios for the panel of 13 neuroblastoma cell lines tested. d) Comparison 
of the differences in G1:S ratio between non-MNA and MNA cell lines 
(p < 0.005 Mann Whitney test). This figure includes data for IMR-32, 
SKNBE1n, SHSY5Y and NGP cells from references 17 and 18. Cell cycle 
experiments were carried out n = 3.
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non-MNA NB69 cell line was more sensitive with maximal levels 
of apoptosis of 55% and 50% at 48 hours measured by FACs and 
Hoechst respectively and the MYCN and MDM2 amplified TR14 
cell line was more resistant with maximal apoptosis being 24% by 
FACs and 18% by Hoechst. Levels of apoptosis were generally higher 
measured by FACs compared with Hoechst, but particularly so for 
GIMEN cells (Fig. 3A and B). There was no cleaved caspase-3 after 
irradiation in GIMEN cells (Fig. 3D) compared with NB69 cells, 
where cleaved caspase-3 was present from 24 hours after irradia-
tion. This confirmed the apoptosis levels measured by Hoechst and 
suggested FACs analysis had over-estimated apoptosis. There was no 
significant difference in levels of apoptosis 96 h post irradiation in 
MNA compared with non-MNA cell lines as determined by FACs. 
However, levels of apoptosis measured by Hoechst were significantly 
higher in MNA cell lines than non-MNA cell lines (p < 0.05).
Effect of induced MYCN expression in 
SHEP Tet21N cells. The p53 downstream 
response to DNA damage was intact in 
both Tet21N MYCN+ and Tet21N MYCN- 
cells (Fig. 4A). p53 levels increased after 
irradiation, although maximal levels were 
observed at different times; 6 hours post 
irradiation (Tet21N MYCN+) and 2 hours 
post irradiation (Tet21N MYCN-). MDM2 
levels in both Tet21N MYCN+ and Tet21N 
MYCN- cells were maximal at 6 hours post 
irradiation, reaching higher levels in the 
Tet21N MYCN+ cells. p21WAF1 increased 
in both Tet21N MYCN+ and Tet21N 
MYCN- cells 24 hours post irradiation. 
The baseline level hypo RB was higher in 
the Tet21N MYCN- compared to Tet21N 
MYCN+ cells. After irradiation hypo RB 
increased in the Tet21N MYCN+ cells to 
maximal levels at 24 hours comparable to 
those in the Tet21N MYCN- cells (Fig. 
4A). Levels of total RB remained constant 
(data not shown).
After irradiation both Tet21N MYCN- 
and Tet21N MYCN+ cells underwent a 
G1 arrest. The G1:S ratio in the Tet21N 
MYCN- cells increased significantly from 
12.7 ± 1.8 in the control to 28.9 ± 
4.5, after irradiation (p < 0.005). The 
G1:S ratio of the Tet21N MYCN
+ cells 
increased significantly from 7.7 ± 0.7 in 
the control to 20.9 ± 2.0 after irradiation (p < 0.005) (Fig. 4B). The 
G1 population was higher in Tet21N MYCN
- cells under normal 
growth conditions: 79.5 ± 2.0% compared with 70.4 ± 1.8% in 
Tet21N MYCN+ cells (Fig. 4B). Growth curve assays revealed that 
Tet21N MYCN+ cells had a faster doubling time of 78.5 ± 1.4 
hours, compared with Tet21N MYCN- cells (90.4 ± 1.2 hours) 
(data not shown). Tet21N MYCN+ cells underwent more apoptosis 
after irradiation than Tet21N MYCN- cells 18.8 ± 3.9 % apoptosis 
compared with 4 ± 1.1 % 72 hours post irradiation respectively (data 
not shown).
The level of Tet21N MYCN expression in the Tet21N SHEP cells 
were compared with the other cell lines at the mRNA and protein 
level (Fig. 4C and D). MYCN mRNA levels in the Tet21N MYCN+ 
cells were similar to the MNA cell lines IMR-32, CHLA-136 and 
PER-108. MYCN protein expression in the Tet21N MYCN+ cells 
Table 2	 MNA	cell	lines	treated	with	siRNA.	MYCN	knockdown	is	the	%	knockdown	of	MYCN	expression	in	siRNA		 	
	 treated	cells	compared	to	the	SCR	control
Cell Line myCn  p53 p21wAF1  hypo RB Total RB sCR siRnA  myCn  sCR Versus  
 Knock Down     g1:s siRnA g1:s myCn siRnA
IMR-32 36-71% 1.2 ± 0.2 14.6 ± 8.1 4.5 ± 2 1.2 ± 0.1 2.6 ± 0.3 5.0 ± 0.5 p < 0.005
NBLW 40-58% 0.8 ± 0.2 1.7 ± 0.3 1.9 ± 0.7 0.8 ± 0.09 2.4 ± 0.1 4.0 ± 0.2 p < 0.001
NGP 66-71% 0.6 ± 0.1 3.7 ± 1.1 2.0 ± 0.5 0.5 ± 0.03 2.8 ± 0.2 7.2 ± 0.3 p < 0.005
SKNBE(2c) 30-62% 0.6 ± 0.2 0.5 ± 0.2 1.2 ± 0.2 0.9 ± 0.1 4.4 ± 0.3 7.3 ± 0.8 p < 0.01
Fold increases for p53, p21WAF1, Hypo RB and total RB are relative to the SCR control. Cell cycle data for the siRNA treated MNA cell lines is expressed as G1:S ratios. The differences in the mean G1:S ratio between MYCN 
siRNA treated and SCR controls were compared using a Mann Whitney test. siRNA experiments were carried out n = 3.
Figure 3. (a) % apoptosis 96 hours post irradiation determined by Hoechst staining (b) % apoptosis deter-
mined by FACs. (c) Cell cycle histograms for the non-MNA LAN-6 and MNA NBLW cell lines. Apoptotic 
cells were present in the sub G1 peak on FL2-H cell cycle histograms (d) cleaved caspase -3 for GIMEN 
and NB69 cells 24-96 hours post irradiation. Apoptosis experiments were carried out n=3.
www.landesbioscience.com Cell Cycle 2643
MYCN and the G1 Checkpoint after DNA Damage
were comparable to MYCN levels observed in MNA cell lines 
(Fig. 4D). Surprisingly, the CHP902R cell line had no MYCN 
mRNA or protein expression despite being MNA. The non-MNA 
LAN-6, NBL-S and SJNB-1 have all been reported to have higher 
levels of MYCN expression compared with other non-MNA cell 
lines,16,20,22 which was confirmed here at the RNA and protein level 
(Fig. 4C and D).
Reduction of MYCN levels using siRNA and the effect on the 
cell cycle. MYCN knockdown using siRNA in 3 MNA p53 wt neuro-
blastoma cell lines: IMR-32, NBLW and NGP caused a significant 
G1 arrest in all 3 cell lines (Table 2 and Fig. 5). Under normal growth 
conditions there was a significant increase in the G1:S ratio between 
the SCR and MYCN siRNA treated IMR-32 control samples (p < 
0.001) (Figs. 5b, c and Table 2). The G1 population increased from 
51.6 ± 1.0 % to 65.5 ± 0.8 % when treated with MYCN siRNA, 
accompanied by a small decrease of 6.9 ± 0.7% in the S-phase 
(Fig. 5B and C). MYCN knockdown in the NGP, NBLW and 
IMR-32 cell lines increased the levels of p21WAF1 and hypo RB 
without affecting p53 protein levels (Table 2 and Fig. 5A). MDM2 
levels also remained unchanged (data not shown). The smaller 
increases in p21WAF1 and hypo RB in NBLW cells may be due to the 
lower levels of MYCN knockdown (Table 2).
MYCN knockdown in the p53 mutant, MNA cell line SKNBE(2c) 
(Fig. 6 and Table 2) also induced a significant G1 arrest (p < 0.01). 
MYCN siRNA treatment increased the G1 population by 8.1 ± 0.9% 
compared with the SCR controls. The S-phase also decreased by 3.9 
± 0.7% (Fig. 6B and C). There were no changes in the levels of CDK 
inhibitors p21WAF1, p27cip/kip or hypo RB after MYCN knockdown 
(Fig. 6A).
The effect of MYCN knockdown on the G1 checkpoint in 
response to irradiation in MNA cell lines. MYCN knockdown 
in MNA cell lines did not restore a G1 arrest in response to DNA 
damage. None of the p53 wt MNA cell lines showed a statistically 
significant increase in G1:S phase ratio after irradiation. The G1:
S ratio of MYCN siRNA treated IMR-32 cells decreased from 5.0 
± 0.5 to 3.1 ± 0.3 after irradiation (Fig. 5B). The G1:S ratio of the 
IMR-32 cells treated with SCR siRNA remained constant at 2.5 ± 
0.3 and 2.6 ± 0.3 in the non-irradiated and irradiated samples respec-
tively. The G1:S ratio of NGP and NBLW cells both decreased after 
irradiation and the cells failed to undergo a G1 arrest regardless of 
MYCN knockdown (data not shown).
DIsCUssIon
Lower levels of p21WAF1 and hypo RB induction and a failure 
to G1 arrest in MNA neuroblastoma cell lines after DNA damage. 
MNA is significantly associated with lower levels of p21WAF1 induc-
tion and hypo RB accumulation and a failure to G1 arrest after 
DNA damage (Table 3). It has previously been suggested that the 
abrogation of G1 arrest in neuroblastoma is caused by dysfunctional 
p21WAF1 unable to bind Cdk2 as immunoprecipitation revealed 
an absence of p21WAF1-cdk2 complexes in NBL-S, SJNB-1 and 
NB1643 cells.16 However, the current study has shown that NBL-S 
and SJNB-1 cells do G1 arrest in response to DNA damage and the 
failure to G1 arrest in MNA neuroblastoma cell lines is more likely to 
be dependent on lower levels of p21WAF1 induction after irradiation, 
as opposed to dysfunctional p21WAF1.
It is possible that the attenuated p21WAF1 induction is due to 
MYCN repression of p21WAF1 after irradiation. After MYCN knock-
down p53 wt MNA cell lines showed increases in p21WAF1 and hypo 
RB, with no change in p53 levels. This would be consistent with 
direct repression of p21WAF1 transcription by MYCN similar to 
p21WAF1 repression by c-MYC.32,33 However, conditional MYCN 
expression in the Tet21N cells to levels comparable with those in 
MNA cell lines did not affect p21WAF1 induction or the G1 check-
point after irradiation. In addition the MYCN over expressing cell 
lines NBL-S, SJNB-1 and LAN-6 all had high p21WAF1 induction 
and underwent a G1 arrest and the MNA CHP902R cell line has 
low MYCN expression and low levels of p21WAF1 induction. Finally, 
MYCN RNAi in 3 wt p53 MNA cell lines did not restore a G1 arrest 
in response to DNA damage. Taken together this data shows lower 
Figure 4. (A) SHEP Tet21N MYCN- and MYCN+ Western blots for 
control and samples harvested 2, 6 and 24 hours post irradiation (n = 3). 
(B) Bar chart for cell cycle data for Tet21N MYCN- and MYCN+ cells in con-
trol and 24 hours post irradiation samples (n = 3). (C) Levels of MYCN mRNA 
expression by real time reverse transcriptase PCR normalised to b-Actin (n = 4). 
(D) Levels of MYCN protein by Western blot for a panel of MNA and 
non-MNA neuroblastoma cell lines.
2644 Cell Cycle 2006; Vol. 5 Issue 22
MYCN and the G1 Checkpoint after DNA Damage
levels of p21WAF1 induction and a failure to 
G1 arrest in response to DNA damage are 
not due to high MYCN expression alone.
Another factor may be cooperating 
with MYCN in MNA cell lines to lower 
p21WAF1 levels such as H-Twist. Levels of 
H-Twist expression have been found to 
correlate strongly with MYCN expression 
in both tumours and cell lines. In addition 
to being apoptotic, H-twist expression has 
been reported to attenuate p53 function 
after irradiation, lowering levels of p21WAF1 
induction. It is possible that H-Twist is 
responsible for the low levels of p21WAF1 
induction and subsequent failure to G1 
arrest observed in this paper. However the 
anti-apoptotic effects described in34 were 
not demonstrated in the panel of cell lines 
tested, as MNA neuroblastoma cell lines 
were more likely to undergo apoptosis than 
non-MNA cell lines 96 hours post irradia-
tion (p < 0.05).
It is also possible that other genetic 
aberrations that coexist with MYCN ampli-
fication may be responsible for the failure 
to G1 arrest in response to DNA damage. 
MNA neuroblastoma cells often have other 
Figure 5. IMR-32 cells treated with siRNA. 
(A) Western blot of IMR-32 cells treated with 
25 nM and 40 nM MYCN siRNA and SCR 
siRNA, Optimem serum free media control 
(Opti) and RPMI 10% FCS control. (B) Cell cycle 
distribution of IMR-32 cells treated with 40 nM 
siRNA (i) control non-irradiated and (ii) 24 hours 
post irradiation. (C) Histogram of nonirradiated 
IMR-32 cells. (siRNA experiments were carried 
out n = 3).
Table 3	 Results	summary
 Low p21wAF1  high p21wAF1  Fail to Do g1  Low %  high %  
 Induction Induction g1 Arrest Arrest Apoptosis Apoptosis 
Non-MNA  NB69 GIMEN GIMEN GIMEN NB69         
n = 7 NBL-S NBL-S SJNB-1       
  SJNB-1  SJNB-1 SHSY5Y  
n =6 for   SHSY5Y SHSY5Y SKNRA     
apoptosis  SKNRA SKNRA LAN-6      
  LAN-6 LAN-6      
    NB69   
    PER108  
MNA  SMSKCNR PER108 SMSKCNR IMR-32 PER108           
n = 10 IMR-32  IMR-32  TR14 SMSKCNR  
 CHLA-136 CHLA-136 NGP CHLA-136        
n =9 for CHP902R CHP902R NBLW       
apoptosis NBLW NBLW LS       
 TR14 TR14 SKNBE(1n)       
 LS  LS    
 NGP   NGP    
 SKNBE(1n)   SKNBE(1n)   
Summary of all 17 cell lines tested for p21WAF1 induction and G1 arrest after irradiation and levels of apoptosis at 96 hours determined by Hoechst staining. High apoptosis > 24% apoptosis (median level of apoptosis 
across the cell lines) and Low apoptosis < 24%
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chromosomal gains and losses that occur in neuroblastoma including 
allelic loss of 1p and 17q gain.35 Alternatively it is possible that the 
expression of coamplified genes on the MYCN amplicon may be 
involved in the failure to G1 arrest, such as DDX1, N‑cym, or NAG. 
Little is known of the functions of genes in the amplicon (reviewed 
in ref. 36).
MNA cell lines are more sensitive to apoptosis after irradiation. 
In this study MNA neuroblastoma cell lines underwent significantly 
higher levels of apoptosis after DNA damage compared with non-
MNA cell lines (Table 3). MYCN may switch the p53 response 
to DNA damage from cell cycle arrest to apoptosis through the 
transcription of apoptosis mediators including PUMA and PIG3 in a 
similar manner to that described for c-MYC.33 The non-MNA NB69 
cell line which had lower levels of p21WAF1 induction than other 
non-MNA cell lines underwent high levels of apoptosis after irradia-
tion and is c-MYC overexpressing.37 Interestingly, MYCN expression 
in the Tet21N cell line increased apoptosis after irradiation (data not 
shown) however the cells still underwent a G1 arrest with high levels 
of p21WAF1 after irradiation (Fig. 4). The MYCN and MDM2 ampli-
fied cell lines TR14 and NGP underwent less apoptosis than other 
MNA cell lines (Table 3), and in addition to lower levels of p21WAF1 
and hypo RB after irradiation, there was also less induction of p53, as 
MDM2 attenuates the function of p53. Lower levels of p53 function 
would prevent apoptotic pathways from being activated.38 The MNA 
IMR-32 cell line also has lower levels of apoptosis compared with 
other MNA cell lines (Fig. 3 and Table 3), which is possibly because 
it is methylated for caspase-8.39
MYCN siRNA alters the proportion of cells in G1. MYCN 
influences control of cell cycle progression, as reduction of MYCN 
expression in 4 MNA cell lines caused a significant increase of cells 
in G1 compared with the SCR siRNA (Table 2). Cell cycle data 
from the SHEP Tet21N experiments supports these findings as 
Tet21N MYCN- cells had a higher G1:S ratio than Tet21N MYCN
+ 
cells under normal growth conditions, and levels of hypo RB were 
higher in control Tet21N MYCN- cells than Tet21N MYCN+ cells, 
indicating that MYCN expression decreased the proportion of cells 
in G1, as previously reported.
7 Studies using protein-nucleic acids to 
selectively inhibit MYCN activity in neuroblastoma cell lines have 
also reported an increase in the G1 population in IMR-32 cells when 
MYCN activity was inhibited.40 In the current study, knockdown 
of MYCN in the 3 p53 MNA wt neuroblastoma cell lines increased 
levels of p21WAF1 and hypo RB without an alteration in p53 levels. 
MYCN knockdown causes a baseline G1 arrest, but knock down of 
MYCN is not sufficient to restore a further increase in G1 arrest after 
DNA damage in MNA cell lines.
MYCN knockdown in the SKNBE(2c) p53 mutant cell line 
induced a significant G1 arrest without accumulation of p21
WAF1 
or hypo RB, indicating that although induction of p21WAF1 after 
MYCN knockdown plays a role in causing a G1 arrest in p53 wt 
neuroblastoma cell lines, p53 mutant cell lines can undergo a G1 
arrest independent of p53, p21WAF1 and p27kip1. In the absence of 
p53 function, MYCN may act downstream of RB to affect the G1 
checkpoint, perhaps by a direct effect on E2F1 as has been suggested 
for c-MYC.41 Knocking down MYCN or inhibiting its activity to 
induce growth arrest may be of benefit clinically in neuroblastomas 
with functional inactivation of the p53 pathway, as is sometimes 
found at relapse.
ConCLUsIons
This study is the first to show that MNA is significantly associ-
ated with lower levels of p21WAF1 induction, hypo RB accumulation 
and a failure to G1 arrest after DNA damage in neuroblastoma cell 
lines. Neuroblastoma cell lines with low levels of p21WAF1 and hypo 
RB induction undergo more apoptosis than those with higher levels 
of p21WAF1 and hypo RB induction. Modulating MYCN expression 
either by conditional expression or MYCN knockdown using siRNA 
in MNA cell lines did not influence the G1 arrest in response to DNA 
damage. We conclude that neuroblastoma cell lines that fail to G1 
arrest have lower levels of p21WAF1 induction and hypo RB accumu-
lation after DNA damage; however the MYCN oncoprotein alone is 
not causally responsible.
Figure 6. SKNBE(2c) cells treated with siRNA. (A) Western blot of SKNBE(2c) 
cells treated with 25 nM and 40 nM MYCN siRNA and SCR siRNA, 
Optimem serum free media control (Opti) and RPMI 10%FCS control. 
(B) Cell cycle distribution of SKNBE(2c) cells treated with 25nM siRNA in 
control non-irradiated cells. (C) Histogram of non-irradiated IMR-32 cells 
(siRNA experiments were carried out (n = 3).
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